Professor of Neurology, Johns Hopkins University School of Medicine
Neurology
Dr. George A. Ricaurte, MD
|
|
Give Review
George A. Ricaurte, MD works in the field of Neurology. He attended Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19 in research and 29 in primary care medicine He received awards:"CMS Meaningful Use Stage 1 Certification". George A. Ricaurte has written publications. He has 100 publications published with PubMed. The lastest publication is: 'Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positr...' George A. Ricaurte, MD accepts all Medicare patients.
Publications
- Methylphenidate and impulsivity: a comparison of effects of methylphenidate enantiomers on delay Discounting in rats.
- Single oral doses of (±) 3,4-methylenedioxymethamphetamine ('Ecstasy') produce lasting serotonergic deficits in non-human primates: relationship to plasma drug and met...
- Studies of ({+/-})-3,4-Methylenedioxymethamphetamine (MDMA) Metabolism and Disposition in Rats and Mice: Relationship to Neuroprotection and NeuroToxicity Profile.
- Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.
- Synthesis and NeuroToxicity Profile of 2,4,5-Trihydroxymethamphetamine and Its 6-(N-Acetylcystein-S-yl) Conjugate.
- Metabolism and Disposition of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") in Baboons After Oral Administration: Comparison to Humans Reveals Marked D...
- Inhibition of 3,4-methylenedioxymethamphetamine metabolism leads to marked decrease in 3,4-dihydroxymethamphetamine formation but no change in serotonin neuroToxicity:...
- Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.
- Sleep deprivation differentially impairs cognitive performance in abstinent methylenedioxymethamphetamine ("Ecstasy") users.
- Further studies on the role of metabolites in (+/-)-3,4-methylenedioxymethamphetamine-induced serotonergic neuroToxicity.
- Direct comparison of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") disposition and metabolism in squirrel monkeys and humans.
- Nonlinear pharmacokinetics of (+/-)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") and its major metabolites in squirrel monkeys at plasma concentrations...
- Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users.
- The effect of catecholamine depletion by alpha-methyl-para-tyrosine on measures of cognitive performance and Sleep in abstinent MDMA users.
- Quantitative positron emission tomography studies of the serotonin transporter in humans previously treated with the appetite suppressants fenfluramine or dexfenfluram...
- Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons.
- Amphetamine treatment similar to that used in the treatment of adult attention-deficit/hyperactivity disorder damages dopaminergic Nerve endings in the striatum of adu...
- Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.
- Identification and characterization of metallothionein-1 and -2 gene expression in the context of (+/-)3,4-methylenedioxymethamphetamine-induced Toxicity to brain dopa...
- Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys.
- Amphetamine neuroToxicity: accomplishments and remaining challenges.
- Positron emission tomography of striatal serotonin transporters in Parkinson Disease.
- Validity of [123I]beta-CIT SPECT in detecting MDMA-induced serotonergic neuroToxicity.
- Cognitive performance of MDMA-treated rhesus monkeys: sensitivity to serotonergic challenge.
- Effect of glucoprivation on serotonin neuroToxicity induced by substituted amphetamines.
- Severe dopaminergic neuroToxicity in primates after a common recreational dose regimen of MDMA ("ecstasy").
- Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions.
- Altered prolactin response to M-chlorophenylpiperazine in monkeys previously treated with 3,4-methylenedioxymethamphetamine (MDMA) or fenfluramine.
- Changes in gene expression linked to methamphetamine-induced dopaminergic neuroToxicity.
- Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.
- Use of MDMA and other illicit drugs by young adult males in northern SPain. A five-year study.
- Dopamine uptake blockers protect against the dopamine depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum.
- Brain dopamine neuroToxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35,428 positr...
- N-methylation dissociates methamphetamine''s neuroToxic and behavioral pharmacologic effects.
- Positron emission tomography imaging of serotonin transporters in the human brain using [11C](+)McN5652.
- Development of PET/SPECT ligands for the serotonin transporter.
- On the neuroToxicity of MDMA and related amphetamine derivatives.
- Serotonin neuroToxicity after (+/-)3,4-methylenedioxymethamphetamine (MDMA; "Ecstasy"): a controlled study in humans.
- Brain serotonin neuroToxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the evidence.
- Highly potent indanamine serotonin uptake blockers as radiotracers for imaging serotonin uptake sites.
- Selective serotonin reuptake inhibitors dissociate fenfluramine's anorectic and neuroToxic effects: importance of dose, species and drug.
- Thalamic hemorrhage with neglect and memory disorder.
- 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl)pyridine: studies on the mechanism of action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- Older dopaminergic neurons do not recover from the effects of MPTP.
- Aging and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced degeneration of dopaminergic neurons in the substantia nigra.
- Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment.
- Neurotoxins, parkinsonism and Parkinson''s Disease.
- The sensitivity of nigrostriatal dopamine neurons to MPP+ does not increase with age.
- The dopamine-depleting effect of 6-hydroxydopamine does not increase with aging.
- Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
- Orally administered MDMA causes a long-term depletion of serotonin in rat brain.
- Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration.
- [3H]3,4-methylenedioxymethamphetamine (MDMA) interactions with brain membranes and glass fiber filter paper.
- 3,4-Methylenedioxyethylamphetamine (MDE), a novel analogue of MDMA, produces long-lasting depletion of serotonin in the rat brain.
- The amine-depleting effects of 5,7-dihydroxytryptamine (5,7-DHT) in C57BL/6 mice do not increase with age.
- Evaluation of the neuroToxic potential of N,N-dimethylamphetamine: an illicit analog of methamphetamine.
- Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine.
- Long-term effects of Chronic methamphetamine administration in rhesus monkeys.
- Chronic idiopathic ataxic neuropathy: neuropathology of a case.
- Responses to i.v. L-tryptophan in MDMA users.
- Studies of MDMA-induced neuroToxicity in nonhuman primates: a basis for evaluating long-term effects in humans.
- Neuroendocrine and mood responses to intravenous L-tryptophan in 3,4-methylenedioxymethamphetamine (MDMA) users. Preliminary observations.
- 5-Hydroxyindoleacetic acid in cerebrospinal fluid reflects serotonergic damage induced by 3,4-methylenedioxymethamphetamine in CNS of non-human primates.
- (+/-)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in nonhuman primates.
- Behavioral effects of N-methylamphetamine and N,N-dimethylamphetamine in rats and squirrel monkeys.
- Modulating role of dopamine on anesthetic requirements.
- Paroxetine as an in vivo indicator of 3,4-methylenedioxymethamphetamine neuroToxicity: a presynaptic serotonergic positron emission tomography ligand?
- Major metabolites of (+/-)3,4-methylenedioxyamphetamine (MDA) do not mediate its Toxic effects on brain serotonin neurons.
- The effects of repeated administration of MDMA on the expression of sexual behavior in the male rat.
- Dexfenfluramine neuroToxicity in brains of non-human primates.
- Aminergic metabolites in cerebrospinal fluid of humans previously exposed to MDMA: preliminary observations.
- Lasting neuropsychiatric sequelae of (+-)methylenedioxymethamphetamine ('ecstasy') in recreational users.
- Reinforcing effects of enantiomers of N,N-dimethylamphetamine in squirrel monkeys.
- In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55.
- [123/125I]RTI-55, an in vivo label for the serotonin transporter.
- Evaluation of the neuroToxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA).
- NeuroToxic amphetamine analogues: effects in monkeys and implications for humans.
- Lasting effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) on central serotonergic neurons in nonhuman primates: neurochemical observations.
- MDMA ("ecstasy") and panic disorder: induction by a single dose.
- Repeated administration of MDMA causes Transient down-regulation of serotonin 5-HT2 receptors.
- Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?
- Synthesis and neuroToxicological evaluation of putative metabolites of the serotonergic neurotoxin 2-(methylamino)-1-[3,4-(methylenedioxy)phenyl] propane [(methylenedi...
- Amphetamine induces depletion of dopamine and loss of dopamine uptake sites in caudate.
- Further evidence that amphetamines produce long-lasting dopamine neurochemical deficits by destroying dopamine Nerve fibers.
- Nerve terminal degeneration after a single injection of D-amphetamine in iprindole-treated rats: relation to selective long-lasting dopamine depletion.
- Increased dopamine metabolism in the rat neostriatum after Toxic doses of d-methylamphetamine.
- Fluoxetine increases long-lasting neostriatal dopamine depletion after administration of d-methamphetamine and d-amphetamine.
- Dopamine Nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain.
- Fenfluramine''s appetite suppression and serotonin neuroToxicity are separable.
- Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study.
- Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine.
- Neurochemical similarities between d,l-cathinone and d-amphetamine.
- Prolactin response to fenfluramine is independent of serotonin release.
- Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; ''ecstasy'').
- Acute poisoning with amphetamines (MDEA) and heroin: antagonistic effects between the two drugs.
- Amphetamine: effects on catecholamine systems and behavior.
- A PET radiotracer for studying serotonin uptake sites: carbon-11-McN-5652Z.
- Strategies for detecting subclinical monoamine depletions in humans.
- In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428.
Schools
Northwestern Center Feinberg School of Medicine
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Carpal Tunnel Syndrome
- Cerebral Artery Thrombosis
- View All
Doctors Specialties
- Neurology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Stanford University -
McGaw Medical Center of Northwestern University -
Northwestern University Feinberg School of Medicine
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Drug Facts
| NPI NUMBER | 1124065503 | |
| NPPES Provider LastName | RICAURTE | |
| NPPES Provider FirstName | GEORGE | |
| NPPES Provider ZIPCode | 212246821 | |
| NPPES Provider State | MD | |
| Specialty Description | Neurology | |
| Total Claim Count | 242.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1124065503 |
| Last Name Of The Provider | RICAURTE |
| First Name Of The Provider | GEORGE |
| View All |
Similar Doctors
|
|
Dr. Joseph H. Miller, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Irene C. Cortese, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald Lesser, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Michael Levy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William Weiner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Leah Blank, MD |
|
|
Dr. Michael S. Phipps, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lisa Shulman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Philip Cherian, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Luis A. Diaz Jr., MD
This Doctor is OpenDoctor Recommended.
|